Merus Announces Recent Corporate Developments and Financial Results for the Fourth Quarter and Full Year 2017
Immunovaccine and Incyte Expand Clinical Collaboration Evaluating Combination Immunotherapies in Advanced Recurrent Ovarian Cancer
New Preclinical Studies Reinforce the Potential for Heightened Anti-Cancer Activity of Combination Therapies Based on Immunovaccine’s Proprietary Delivery Platform
Immunovaccine Announces Initiation of Patient Dosing in Investigator-Sponsored Phase 2 Clinical Trial
Helix BioPharma Appoints Deloitte as Strategic Advisor to Explore Partnering and Licensing Opportunities
Published Study Demonstrates the Association Between Immunovaccine’s Proprietary Immune-targeted Delivery Technology
Merus Announces First Patient Dosed in a Phase 2 Clinical Trial of MCLA-128 in Two Metastatic Breast Cancer Patient Populations
Precious Metals & Critical Minerals Hybrid Investor Conference: Presentations Now Available for Online Viewing
